DtA, GNOSTIC MICROBIOLOG AND

INFECTIOUS DISEA, SE

Volume 12 (1989) Contents

NUMBER 1, JANUARY/FEBRUARY

Mycology Susceptibility of Nosocomial Isolates of Candida Species to LY121019 and Other Antifungal Agents

M.A. Pfaller, S. Wey, T. Gerarden, A. Houston, and R.P. Wenzel

Virology Screening with a Shell Vial Assay for Antiviral Activity Against Cytomegalovirus

A. Telenti and T.F. Smith

5

Antimicrobial Susceptibility Studies In Vitro Activity of Ampicillin/Sulbactam Against Enterococci Determined by the Time-kill Method Richard F. D.'Amato, Anna Mathew, Lisa Hochstein, Dennis J. Cleri, and Janet Johnson

DNA Hybridization Studies of a Nucleotide Sequence Homologous to Transposon TN1545 in the "Minnesota" Strain of Multiresistant Streptococcus pneumoniae Isolated in 1977

Robert C. Cooksey, Jana M. Swenson, Nancye C. Clark, and Clyde Thornsberry

13

Case Report Successful Treatment of Progressive Disseminated Histoplasmosis with Amphotericin B Methyl Ester

Robert E. Neihart, Daniel R. Hinthorn, Paul D. Hoeprich, and Chien Liu

17

Book Review 21

SYMPOSIUM: N E W F I N D I N G S O N THE ANTIBACTERIAL I N T E R A C T I O N BETWEEN CEFOTAXIME A N D DESACETYLCEFOTAXIME Introduction

Ronald N. Jones and Harold C. Neu

23

Antimicrobial Activity of Lomefloxacin (NY-198, SC 47111) Against Bacterial Strains from Venezuela 41S

J.R. Torres

A Ten-Laboratory Study of Lomefloxacin (NY-198 or SC 47111) Antimicrobial Activity in Argentina 458

H.N. Bianchini, B. Sarachian, A. Fernandez, R. Paolasso, C. Kaufman, R. Notario, G. Porven, R.A. Ingaramo, S. Perez, and S.M. Ferrero

In Vitro Evaluation of Lomefloxacin Activity in Colombia 51S

H. Trujillo, G.I. mejia de R., L. Castrillon de P., and C. Gomez

In Vitro Antimicrobial Activity and Postantibiotic Effect of Lomefloxacin, a New Difluoroquinolone 53S

GabrieIla Molinari, Ruggero Bandelloni, Paola Paglia, Eugenio Debbia, and Gian Carlo Schito

Evaluation of In Vitro Antimicrobial Activity of Lomefloxacin Against Staphylococci, Enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa 57S

Gian Maria Rossolini, Silvia Valentini, and Giuseppe Satta

Comparative In Vitro Activity of Lomefloxacin, a Difluoro-quinolone 65S

M.]. Robbins, A.J. Baskerville, M. Sanghrajka, G. Mumtaz, D. Felmingham, G.L. Ridgway, and R.N. Gffineberg

Lomefloxacin, a New Difluoroquinolone: In Vitro Activity Against Gram- Positive and Gram-Negative Bacteria 77S

Daryl Hoban, Myra Grabowski, Joan Koss, and Val Weselowski

In Vitro Activity of Lomefloxacin Against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum 83S Daryl Hoban, Pat DeGagne, and Evelyn Witwicki

In Vitro Activity of Lomefloxacin (SC 47111 or NY-198) Against Chlamydia trachomatis Strains 87S

John Segreti, Harold A. Kessler, Kathi Kapell, and Gordon M. Trenholme

In Vitro Activity of Lomefloxacin (SC 47111 or NY-198) Against Isolates of Legionella Spp. 89S

Jacques Dubois and Jean R. Joly

In Vitro Activity of Lomefloxacin (NY-198 or SC 47111), Ciprofloxacin, and Erythromycin Against 100 Clinical Legionella Strains 93S

Paul H. Edelstein, Elizabeth A. Gaudet, and Martha A.C. Edelstein

In Vitro Activity of Lomefloxacin (NY-198 or SC 47111) 97S

P.M. Shah, S. M~iller, J. Kipp, and W. Stille

Summation 103S Ronald N. Jones and Harold C. Neu

NUMBER 4 SUPPLEMENT, JULY/AUGUST

Introduction

Harold C. Neu

I. N e w Understandings of Resistance and Modes of Action Overview of Mechanisms of Bacterial Resistance

H.C. Neu

107S

109S

Mechanisms of Resistance in Anaerobes and New Developments in Testing 117S

Sydney M. Finegold

Mechanism of Beta-Lactamase Inhibition: Differences Between Sulbactam and Other Inhibitors 121S

Tetsuo Sawai and Akihito Yamaguchi

Induction of Beta-Lactamase in Gram-Negative Bacteria 131S

B. Wiedemann and K. Peter

Sulbactam: Secondary Mechanisms of Action 139S

A. Kazmierczak, A. Pechinot, E. Siebor, X. Cordin, and R. Labia

The In Vitro Effect of Sulbactam on Polymorphonuclear Leukocyte Function 147S

Jose Ignacio Santos and Antonio Arbo

II. The Role of a Beta-Lactamase Inhibitor in the Treatment of Infections Antibiotic Resistance in Australia with Special Reference to Sulbactam/Ampicillin 153S

C.J. Fernandes and V.P. Ackerman

Patterns of Resistance to Anaerobic Organisms in Australia 159S

Rosemary Munro

In Vitro Activity of Sulbactam in Combination with Various Beta-Lactam Antibiotics 165S

Jean Klastersky and Philippe Van der Auwera

Clinical Evaluation of Sulbactam/Ampicillin in Japan 171S

Kaoru Shimada

Sulbactam/Ampicillin Followed by Oral Treatment with Sultamicillin for Medical and Surgical Infections 175S

Sun Talk Chang, Hee Young Chung, Soo Dong Pal, and Jung Hee Lee

Intravenous Sulbactam/Ampicillin in the Treatment of Pediatric Infections 179S

Chin-Yun Lee, Tsou-Yien Lin, Mong-Ling Chu, Ming-Jenn Lee, Ching-Ying Hsu, Li-Min Huang, and Chong-Ming Chen

Sulbactam/Ampicillin in the Treatment of Pediatric Infections 185S

G. Kanra, G. Secmeer, E. Akalin, Z. Ecevit, A.SI Calikoglu, M. Gunel, and O. Tarim

Sulbactam/Ampicillin Versus Metronidazole/Gentamicin in the Treatment of Post-Cesarean Section Endometritis 189S

Mark G. Martens, Sebastian Faro, Hunter A. Hammill, Dorothy Smith, Gerry Riddle, and Maurizio Maccato

The Treatment of Intraabdominal Infections in Surgery 195S

Ronald Lee Nichols

III. Infections in the Immuno-Compromised Host: Epidemiology and New Modalities for Treatment A Review of Chemoprophylaxis and Therapy of Bacterial Infections in Neutropenic Patients 201S

Jean Klastersky

In Vitro Assessment of Sulbactam Plus Cefoperazone in the Treatment of Bacteria Isolated From Cancer Patients 209S

Gerald P. Bodey, Peggy Miller, and Dah Hsi Ho

Efficacy of Sulbactam/Cefoperazone for the Treatment of Infections in Patients with Hematologic Diseases 215S

Atsushi Horiuchi, Hirofumi Hasegawa, Takashi Kageyama, Tsuyoshi Yonezawa, Teruo Kitani, Tohru Masaoka, Kojiro Yasunaga, Hiroyo Kawagoe, and Kiyoyasu Nagai

Fungal Infections in the Immunocompromised Host 221S

David K. Stein and Alan M. Sugar

Review of Fluconazole: A New Triazole Antifungal Agent 229S

H. Washton

Efficacy of Fluconazole in Cryptococcal Meningitis 235S

P.D. Jones, D. Marriott, and B.R. Speed

A Clinical Study of Fluconazole for the Treatment of Deep Mycoses 239S

Hideo Ikemoto

Summary of Conference 249S

Harold C. Neu

A Review of Cephalosporin Metabolism: A Lesson To Be Learned for Future Chemotherapy

Ronald N. Jones

Comparative In Vitro Activity of Cefoxitin, Cefotaxime Alone, and in Combination with Desacetylcefotaxime Against the BacteroidesSpecies

Hanna N. Canawati

Effectiveness of Cefotaxime Alone and in Combination with Desacetylcefotaxime Against Bacteroides fragilis

Benedict L. Wasilauskas

Comparison of the In Vitro Action and Interaction of Cefotaxime and Desacetylcefotaxime Against Clinical Isolates of Bacteroides spp.

Kenneth E. Aldridge

Activity of Cefotaxime/Desacetylcefotaxime with Two Aminoglycosides Against Gram-Negative Pathogens: An Example of Interactive Synergy

Stephen G. Jenkins

Evaluation of Cefotaxime Alone and in Combination with Desacetylcefotaxime Against Strains of Staphylococcus aureus That Produce Variants of Staphylococcal ~-Lactamase

Charles W. Stratton, Douglas S. Kernodle, Susan C. Eades, and Lyndell S. Weeks

Antibacterial Activity of Cefotaxime, Desacetylcefotaxime, and the Combination of the Two

Henrik Friis

Synergistic Interaction of Cefotaxime and its Metabolite Desacetylcefotaxime Demonstrated by Drug-Impregnated Disks

Dennis L. Stevens, Roberta Bergstrom, and Amy Gibbons

Evaluation of Disk Susceptibility Testing of Cefotaxime/Desacetylcefotaxime

Peter C. Fuchs, Ronald N. Jones, and Arthur L. Barry

Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in the Newborn

Y. Aujard, F. Brion, F. Jacquz-Aigrain, M.C. Kasse, P. Chretien, C. Criqui, and H. Mathieu

Cefotaxime and Desacetylcefotaxime in Neonates and Children: A Review of Microbiologic, Pharmacokinetic, and Clinical Experience

Richard F. Jacobs and Gregory L. Kearns

Optimal Cefotaxime Dosing for Gram-Negative Bacteremia Effective Trough Serum Bactericidal Titer and Drug Concentrations 8 and 12 Hr. After 1- or 2-G Infusions

Hewitt C. Goodpasture, E. Hugh Gerlach, Ronald N. Jones, and Jerry D. Peterie

Comparative Study of Three Different Dosing Regimens for Cefotaxime for Treatment of Gram-Negative Bacteremia

Gordon M. Trenholme, Barbara A. Schmitt, Jeffrey A. Nelson, Loretta C. Gvazdinskas, Barbara B. Harrison, and George W. Parkhurst

Antibiotics for Penetrating Abdominal Trauma: A Prospective Comparative Trial of Single Agent Cephalosporin Therapy Versus Combination Therapy

Brack A. Bivins, Larry Crots, Farouck N. Obeid, Victor J. Sorensen, H. Mathilda Horst, and John J. Fath

Cephalosporins Cefotaxime/Desacetylcefotaxime Revisited: A Summary

Harold C. Neu

25

33

39

45

51

57

67

73

81

87

93

101

107

113

119

NUMBER 2, MARCH/APRIL

Bacteriology Absence of Factors Associated with Significant Urinary Tract Infections Caused by Coagulase-Negative Staphylococci

David Rimland and William Alexander

Identification of Neisseria gonorrhoeae with the ORTHOProbe DNA Probe Test

Alex P. Kuritza, Stephen C. Edberg, Cynthia Chapis, and Patricia GalIo

123

129

Virology Improved Sensitivity of a Modified Polymerase Chain Reaction Amplified DNA Probe in Comparison with Serial Tissue Culture Passage for Detection of Chlamydia trachomatis in Conjunctival Specimens from Nepal

Deborah Dean, Chet Raj Pant, and Peter O'Hanley

Evaluation of Assay Systems for the Detection of Rotavirus in Stool Specimens

John J. Mathewson, Donald K. Winsor, Jr., Herbert L. Dupont, and Sandra L. Secor

133

139

Antimicrobial Susceptibility Studies In Vitro Activity of RO 23-9424, Ceftazidime, and Eight Other Newer Beta-Lactams Against 100 Gram-Positive Blood Culture Isolates 143

Ronald N. Jones and Arthur L. Barry

Effect of Blood Product Medium Supplements on the Activity of Cefotaxime and Other Cephalosporins Against Enterococcus faecalis 149

G.M. Eliopoulos, E. Reiszner, S. Willey, W.J. Novick, Jr., and R.C. Moellering, Jr.

Comparative In Vitro Susceptibilities of 504 Bacteremic Isolates to Ticarcillin Plus Clavulanic Acid and Other Antimicrobial Agents 157

Coleman Rotstein, Daniel Amsterdam, Thomas Beam, Jr., and Eugene Gorzynski

Comparison of the Bactericidal Activity of Cefotaxime and Desacetylcefotaxime Alone and in Combination Against Bacteroides fragilis Group Organisms 165

Kenneth E. Aldridge, Lyndell S. Weeks, Charles W. Stratton, and Charles V. Sanders

Effects of Escherichia coli Spheroplast Formation on Assays of H2 and Adenosine Triphosphate Based Ampicillin Susceptibility Tests 171

E.G. H6rnsten, L.E. Nilsson, H. Elwing, and I. Lundstr6m

Clinically Significant Differences in Antibiograms of Morphologic Variants of Blood Culture Isolates 177

Lois B. Travis and James D. MacLowry

Antimicrobial Clinical Studies Pharmacokinetics and Safety of Lomefloxacin Following Multiple Doses Thomas L. Hunt and Margaret A. Adams

Case Reports Septic Arthritis of the Knee Due to Streptococcus anginosus

Larry T. Balentine, Christopher J. Papasian, and Cynthia Burdick

181

189

Mycoplasma hominis Septic Thrombophlebitis in a Patient with Multiple Trauma: A Case Report and Literature Review

Octavio V. Martinez, Joseph Chan, Timothy Cleary, and Gail H. Cassell

Book Review

193

197

NUMBER 3, MAY/JUNE

Bacteriology Neutrophil Killing of Single Microorganisms as Measured by a New Method 199

K.O. Dugger and J.N. Galgiani

A Comparison of the Rapid Thermonuclease Test and the Lysostaphin Susceptibility Test in the Presumptive Identification of Staphylococcus aureus from Positive Bactec Blood Cultures 205

K.R. Forward, E.G. Ongsansoy, and T.K. Mathew

Comparison of AMS-Vitek, MicroScan, and Autobac Series II for the Identification of Gram-Negative Bacilli 211

Allan L. Truant, Elaine Starr, Christina A. Nevel, Maria Tsolakis, and Ellen F. Fiss

Mycobacteriology Mycobacteremia Caused by Simultaneous Infection with Mycobacterium avium and Mycobacterium intracellulare Detected by Analysis of a BACTEC 13A Bottle with the Gen-Probe Kit

Patricia S. Conville, John F. Keiser, and Frank G. Witebsky

Lomefloxacin, a New Fluoroquinolone: Studies on In Vitro Antimicrobial Spectrum, Potency, and Development of Resistance

Kenneth E. Aldridge, Amy Henderberg, Kathleen Gebbia, Denise D. Schiro, Ailleen Janney, and Charles V. Sanders

Antimicrobial Susceptibility Studies A Sensitive Bioassay for Teicoplanin in Serum in the Presence or Absence of Other Antibiotics

R.C. Erickson, A.R. Hildebrand, P.F. Hoffman, and C.B. Gibson

Comparative In Vitro Activity of a New Fluorinated 4-Quinolone, QA-241

Wei-Wei Niu and Harold C. Neu

In Vitro Activity of Minocycline and Rifampin Against Staphylococci

John Segreti, Loretta C. Gvazdinskas, and Gordon M. Trenholme

Antimicrobial Clinical Studies The Use of Cefepime (BMY 28142) to Treat Respiratory Infections

Neville Clynes, Brian E. Scully, and Harold C. Neu

Case Reports Vertebral Osteomyelitis and Native Valve Endocarditis Caused by Staphylococcus warneri

Craig A. Wood, David L. Sewell, and Larry J. Strausbaugh

217

221

235

243

253

257

261

Corynebacterium Jeikeium (Group JK Diptheroids) Endocarditis: A Report of Five Cases

B. Vanbosterhaut, I. Surmont, J. Vandeven, G. Wauters, and J. Vandepitte

Notes Evaluation of a New Herpes Simplex Virus Typing Reagent for Tissue Culture Confirmation

Sandra L. Aarnaes, Ellena M. Peterson, and Luis M. de la Maza

Stability of SM-7338, a New Carbapenem in Mediums Recommended for the Susceptibility Testing of Anaerobic Bacteria and Gonococci

Ronald N. Jones and Richard V. Gardiner

Correlation of Urine pH with the Detection of Cytomegalovirus by the Shell Vial Technique

Larry D. Gray, Duane M. IIstrup, and Thomas F. Smith

In Vitro Evaluation of Ramoplanin (A16686 or MDL62198): A New Depsipeptide Complex for Potential Topical Use

Ronald N. Jones and Arthur L. Barry

Resistance of Xanthomonas maltophilia to Antibiotics and the Effect of Beta-lactamase Inhibitors

Harold C. Neu, Gita Saha, and Nai-Xun Chin

Letter to the Editor

Book Review

265

269

271

275

279

283

287

289

NUMBER 4, JULY/AUGUST

Bacteriology High Incidence of False Positives by a Latex Agglutination Test for the Diagnosis of Clostridium difficile Associated Colitis in Compromised Patients

S.M. Hussain Qadri, Javed Akhter, S. Ostrawski, S.G.M. Qadri, and Burke A. Cunha

The Application of Molecular and Immunologic Techniques to Study the Epidemiology of Legionella pneumophila Serogroup 1

Michael Pfaller, Richard Hollis, William Johnson, R. Michael Massanari, Charles Helms, Richard Wenzel, Nancy Hall, Nelson Moyer, and Jean Joly

Mycobacteriology Evaluation of Four Mycobacterial Blood Culture Media: BACTEC 13A, Isolator/BACTEC 12B, Isolator/Middlebrook Agar, and a Biphasic Medium Michael B. Agy, Carolyn K. Wallis, James J. Plorde, Larry C. Carlson, and Marie B. Coyle

Comparison of Three Techniques for Concentrating Positive BACTEC 13A Bottles for Mycobacterial DNA Probe Analysis

Patricia S. Conville, John F. Keiser, and Frank G. Witebsky

291

295

303

309

Virology Evaluation of a HSV Specific Monoclonal Antibody Reagent for Laboratory Diagnosis of Herpes Simplex Virus Infection

Curt A. Gleaves, Daniel H. Rice, Rani Bindra, Debby A. Hursh, Susan E. Curtis, Carrie F. Lee, and Sharon F. Wendt

Evaluation of Three Enzyme Immunoassays for HIV-1 Antigen Detection Patricia B. Willoughby, Arturo Lisker, and James D. Folds

Detection of Multiple Viral Agents in Nasopharyngeal Specimens Yielding Respiratory Syncytial Virus (RSV): An Assessment of Diagnostic Strategy and Clinical Significance

E. Kanta Subbarao, Judy Griffis, and Joseph L. Waner

Herpesvirus simiae Contamination of Primary Rhesus Monkey Kidney Cell Cultures: CDC Recommendations to Minimize Risks to Laboratory Personnel

D.L. Wells, S.L. Lipper, J.K. Hilliard, J.A. Stewart, G.P. Holmes, K.L. Herrmann, M.P. Kiley, and L.B. Schonberger

Antimicrobial Susceptibility Studies In Vitro Comparison of Cefpirome and Four Other Beta-Lactam Antibiotics Alone and in Combination with Tobramycin Against Clinical Isolates of Pseudomonas aeruginosa

I. Cabezudo, M. Pfaller, M. Bale, and R. Wenzel

Synergy of New C-3 Substituted Cephalosporins and Tobramycin Against Pseudomonas aeruginosa and Pseudomonas cepacia

Nai-Xun Chin and Harold C. Neu

315

319

327

333

337

343

Case Reports Agrobacterium radiobacter and CDC Group Ve-2 Bacteremia

Dean A. Blumberg and James D. Cherry

Varicella Associated Intracerebral Hemorrhage in the Absence of Thrombocytopenia EroI Fikrig and NeiI L. Barg

N o t e s Rapid Culture Confirmation of Adenovirus Isolates Using the Adenoclone Enzyme Immunoassay (EIA) Test Kit

Steven M. Lipson

Should Novobiocin Be Clinically Re-evaluated?

Ronald N. Jones

351

357

361

363

NUMBER 5, SEPTEMBER/OCTOBER

New Antimicrobial Reviews Cefmetazole (CS-1170), a "New" Cephamycin with a Decade of Clinical Experience RonaId N. Jones

367

Bacteriology Detection of Staphylococcal Resistance to Penicillinase-Resistant Penicillins: A Comparison of Two Widely Used Disk Diffusion Methods 381

Ronald N. Jones and Arthur L. Barry

The Prevalence of Staphylococcal Resistance to Penicillinase-Resistant Penicillins: A Retrospective and Prospective National Surveillance Trial of Isolates From 40 Medical Centers 385 Ronald N. Jones, Arthur L. Barry, Richard V. Gardiner, and Richard R. Packer

Comparative Evaluation of the MRS Test: A 4 to 6 Hour Screening Test for Detecting Oxacillin-Resistant Staphylococci 395

Sybil Wellstood

Mycobacteriology Inter-Bottle Transfer of Mycobacteria by the BACTEC 460

Patricia S. Conville and Frank G. Witebsky

Virology Evaluation of Immunofluorescent Reagents, Centrifugation, and Conventional Cultures for the Diagnosis of Adenovirus Infection

Azmi M. Mahafzah and Marie L. Landry

Antimicrobial Susceptibility Studies Statistical Criteria for Selecting Quality Control Limits for Broth Microdilution Susceptibility Tests with 39 Different Antimicrobial Agents

Arthur L. Barry, Peter C. Fuchs, Ronald N. Jones, and The Collaborative Antimicrobial Susceptibility Testing Group

In Vitro Comparison of Cefoperazone/Sulbactam with Selected Antimicrobials Against 300 Bacteroides Isolates: Inhibitory Activity and Time-Kill Kinetic Studies

Michael S. Gelfand, Jane T. Grogan, and Michael J. Haas

Case Report Invasive Hyalohyphomycosis Caused by Scopulariopsis brevicaulis in a Patient Undergoing Allogeneic Bone Marrow Transplant

Peter Phillips, William S. Wood, Gordon Phillips, and Michael G. Rinaldi

401

407

413

421

429

Notes Comparative Susceptibility of Mycoplasma pneumoniae to Erythromycin, Ciprofloxacin, and Lomefloxacin 433

G.H. Cassell, K.B. Waites, M.S. Pate, K.C. Canupp, and L.B. Duffy

The Comparative Activity of Lomefloxacin (SC-47111, NY-198) and Other Orally Absorbable Agents Against Haemophilus influenzae and Branhamella catarrhalis 437

K.R. Forward, P.A. Degagne, and K.R. Bartlett

Antibacterial Activity and Beta-Lactamase Stability of MDL 19,592, an Oral Cephalosporin 441

Kwok-Woon Yu and Harold C. Neu

PBP Profiles of Haemophilus influenzae, H. aegyptius, and the H. influenzae Biogroup Aegyptius Associated with Brazilian Purpuric Fever

Paul M. Mendelman and Donald O. Chaffin

Bioassay of Teicoplanin in Serum Containing Rifampin or a Beta-Lactam Antibiotic

M.T. Kenny, J.K. Dulworth, M.A. Brackman, H.L. Torney, C.B. Gibson, A.R. Hildebrand, L.S. Weckbach, and J.L. Staneck

Book Review

445

449

455

NUMBER 6, NOVEMBER/DECEMBER

Bacteriology Comparison of Two Commercial Broth-Culture Systems for Microbial Detection in Dialysates of Patients on Continuous Ambulatory Peritoneal Dialysis

Michael A. SauboIle, David L. Sewell, Marline D. Holland, and Thomas A. Golper

Increased Efficiency of Stool Culture for the Detection of Salmonella and Shigella

Daniel P. Fedorko, Susan M. Lehman, Pauline K.W. Yu, Jeffrey J. Germer, and John P. Anhalt

Mycology Susceptibility of Clinical Isolates of Candida spp. to Terconazole and Other Azole Antifungal Agents

M.A. Pfaller and T. Gerarden

Virology Replacement of Special Enzyme Immunoassay Transport Medium by a Standard Viral Transport Medium in the Herpcheck Herpes Simplex Virus and Antigen Detection Test

Andr~ Dascal, Jacques Chan-Thim, Marie Morahan, Joseph Portnoy, and Jack Mendelson

Antimicrobial Susceptibility Studies Tazobactam Prevention of Emergence of Resistance

Harold C. Neu, Wei-Wei Niu, and Nai-Xun Chin

Comparative In Vitro Activity of Piperacillin Combined with the Beta-Lactamase Inhibitor Tazobactam (YTR 830)

G.M. Eliopoulos, K. Klimm, M.J. Ferraro, G.A. Jacoby, and R.C. Moellering, Jr.

Piperacillin/Tazobactam (YTR 830) Combination: Comparative Antimicrobial Activity Against 5889 Recent Aerobic Isolates and 60 Bacteroides fragilis Group Strains

Ronald N. Jones, Michael A. Pfaller, Peter C. Fuchs, Kenneth Aldridge, Stephen D. Allen, and E. Hugh Gerlach

Studies to Optimize the In Vitro Testing of Piperacillin Combined with Tazobactam (YTR 830)

Ronald N. Jones and Arthur L. Barry

457

463

467

473

477

481

489

495

Activity of TicarcillinYClavulanate and Piperacillin/Tazobactam (YTR 830; CL-298,741) Against Clinical Isolates and Against Mutants Derepressed for Class I Beta-Lactamase

Cynthia C. Knapp, Juan Sierra-Madero, and John A. Washington

Case Report Nocardia Infection in the Acquired Immunodeficiency Syndrome

Edward E. Telzak, John Hii, Bruce Polsky, Timothy E. Kiehn, and Donald Armstrong

Notes Rapid Identification of Candida albicans Using 4-Methylumbelliferyl N-acetyl-~-galactosaminide

Maurice T. Dalton, David J.M. Haldane, and June MacDonald

Book Review

Author Index

Subject Index

Volume Contents

511

517

521

525

527

529

NUMBER 3 SUPPLEMENT, MAY/JUNE

Lomefloxacin (SC 47111 or NY-198), a New Difluorinated Quinolone: Comparison of the In Vitro Activity with Other Broad Spectrum Antimicrobials Against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa 1S

Kenneth E. Aldridge, Amy Henderberg, and Charles V. Sanders

Comparative In Vitro Activity of Lomefloxacin (SC 47111 or NY-198) Against Fresh Clinical Bacterial Isolates 7S

D.N. Wright, B. Saxon, and J.M. Matsen

In Vitro Activity of Lomefloxacin Against Multiply Resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis 13S

Cathy A. DiVincenzo, Kari L. Shatzer, and Frank R. Venezio

In Vitro Activity of Lomefloxacin as Compared with Ciprofloxacin 17S Clark B. Inderlied, Mariselle G. Lancero, Luis M. Bermudez, and Lowell S. Young

In Vitro Activity of Lomefloxacin (SC 47111 or NY-198), a New Quinolone Antimicrobial, Against Clinical Isolates of Common Pathogens 21S

S.A. Sonstein and J. Dahlgren

Bactericidal Activity of Lomefloxacin SC 47111 (NY-198) and Ciprofloxacin Against Selected Pathogens 29S Charles W. Stratton and LyndeU S. Weeks

Lomefloxacin Activity Against 2,813 Clinical Isolates: A Collaborative Study at Three Medical Centers in Brazil 35S Marcelo Magalhaes, Luiz R. Trabulsi, and Augusto C. Montelli